NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
ID: 346990Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $700K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/346990

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-269.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, a federal grant opportunity aimed at funding innovative research that addresses HIV-related issues in the context of substance use disorders. This program seeks exceptionally creative scientists to propose transformative research approaches that diverge from existing projects and align with NIH HIV/AIDS research priorities, ultimately aiming to improve health outcomes for individuals affected by HIV and substance use disorders. Eligible applicants include a wide range of institutions and organizations, with a maximum funding amount of $700,000 per year available for up to five years. Interested parties should submit their applications by August 14, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-269-Full-Announcement.html
    PAR-23-269.html
    The NIDA Avant-Garde Program for HIV and Substance Use Disorder Research aims to fund innovative studies addressing HIV-related issues in the context of substance use disorders (SUD). This initiative, under the National Institutes of Health (NIH), encourages exceptionally creative scientists to propose transformative approaches that could lead to significant advancements in HIV treatment and prevention for people with SUD. Emphasis is placed on pioneering research that diverges from existing projects and aligns with NIH HIV/AIDS research priorities. Eligible applicants include various institutions and organizations, such as higher education institutions, nonprofits, and government agencies. The funding opportunity has a maximum budget of $700,000 per year for up to five years. Applications must comply with specific submission guidelines and deadlines, with additional documentation such as letters of reference and a detailed research plan required. The review process prioritizes the project's potential impact, innovation, and the qualifications of the principal investigator. Ultimately, this funding opportunity seeks to support groundbreaking research that can substantially improve health outcomes for individuals affected by HIV and substance use disorders.
    Similar Opportunities
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    Avenir Award Program for Research on Substance Use Disorders and HIV (DP2 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Avenir Award Program for Research on Substance Use Disorders and HIV, aimed at supporting early-stage investigators conducting innovative research at the intersection of HIV and substance use. This grant program encourages studies that align with NIH HIV/AIDS research priorities, focusing on reducing HIV transmission, optimizing therapies for co-occurring conditions, and enhancing treatment strategies for affected populations. Eligible applicants include a diverse range of institutions such as higher education institutions, non-profits, and government agencies, with a budget cap of $375,000 annually for up to four years, totaling $1.5 million in direct costs. Interested parties can find more information and application details at the provided NIH link, with the application deadline set for August 15, 2025.
    Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Exploratory Studies to Investigate Mechanisms of HIV infection, Replication, Latency, and/or Pathogenesis in the Context of Substance Use Disorders" through the R01 Research Project Grant. This initiative aims to support innovative and high-risk studies that explore the molecular mechanisms linking HIV and substance use disorders (SUDs), with a focus on advancing understanding of HIV dynamics within the Central Nervous System (CNS). The total estimated program funding is $2 million for fiscal year 2026, with the potential to support up to three awards, and applications must include clear milestones and human or primate studies. Interested applicants should note that the deadline for submitting letters of intent and applications is July 14, 2025, and no clinical trials are permitted under this grant. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)" aimed at supporting innovative research at the intersection of HIV and substance use. This initiative seeks proposals that address critical gaps in understanding and improving health outcomes for individuals living with HIV who also face substance use disorders, requiring detailed research plans and preliminary data from both individual researchers and research teams. NIH plans to allocate approximately $3 million annually for three to five awards over three years, with applications due by January 11, 2025, and a strong emphasis on enhancing diverse perspectives through an inclusion plan. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-024.html.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)." This initiative aims to encourage research into the role of inflammasomes in the neuropathology associated with HIV infection and substance use disorders, particularly focusing on their impact on neurocognitive disorders and immune function. The program seeks to bridge knowledge gaps in treatment and research by exploring how inflammasome activation is influenced by HIV and substance use, with the goal of translating findings into clinical applications. A total funding amount of $2 million is available to support up to four grants, with a submission deadline of February 13, 2024. Interested applicants can find more information and application guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting grant applications for the initiative titled "Ex Vivo Models for Studies at the Intersection of HIV and Poly-Substance Use (R01 Clinical Trial Not Allowed)." This funding opportunity aims to investigate the neuroimmune and neuronal-glial mechanisms associated with HIV-associated neurological disorders (HAND) using advanced ex vivo culturing platforms derived from human induced pluripotent stem cells (hiPSC) in the context of addictive substances. The research is critical for understanding the genetic, epigenetic, and neuroimmune interactions that contribute to HAND, particularly in the presence of substances like opioids and cocaine. The NIH has committed a total of $2 million annually for Fiscal Years 2024-2026, with applications due by 5 PM local time on August 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for exploratory studies focused on the mechanisms of HIV infection, replication, latency, and pathogenesis in the context of substance use disorders (SUDs). This initiative aims to support high-risk, high-impact research that utilizes innovative tools to investigate the interactions between HIV and addictive substances, with a particular emphasis on understanding the molecular mechanisms involved and the effects of these substances on HIV latency and replication. The total funding budget for this opportunity is $2 million, intended to support three awards, each capped at $700,000 in direct costs annually. Applications are due by July 14, 2024, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-25-011.html.
    Targeting Inflammasomes in HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use" (RFA-DA-25-069). This initiative aims to support research that elucidates the mechanisms of inflammasome activation related to neurocognitive disorders in individuals affected by HIV and substance use disorders (SUDs), focusing on identifying molecular markers and understanding the inflammatory responses triggered by these conditions. The program is significant for developing new therapeutic tools that could enhance clinical outcomes for affected populations. Up to four grants, totaling $2 million, will be awarded, with applications due by March 14, 2025. For further inquiries, interested applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage for detailed application instructions.
    Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Research on the Neuro-Immune Axis in the context of HIV and Substance Use," aimed at advancing the understanding of the interplay between neuroimmune networks and the effects of HIV and substance use disorders (SUD). This R01 Clinical Trial Not Allowed grant seeks applications that explore neuroimmune interactions, therapeutic targets, and modulatory tools, with a focus on examining the molecular mechanisms and regulatory pathways influenced by substance use in relation to HIV pathogenesis. The opportunity is significant for addressing HIV-related neurological issues exacerbated by substance abuse, with a total funding of up to $2 million projected for FY 2025 to support up to six projects. Interested applicants must submit their proposals by November 13, 2024, and can find additional information and application instructions at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at supporting exploratory research into the neuroimmune connections related to HIV and substance use disorders. This initiative seeks to identify and characterize neuroimmune networks and communication pathways, as well as discover novel modulatory tools that can enhance understanding of the regulatory mechanisms contributing to the comorbidity of HIV and substance use disorders. The NIH intends to allocate up to $2 million to fund approximately six awards, with individual budgets not exceeding $275,000 over a two-year period. Interested applicants must submit their proposals by November 13, 2024, and can find additional information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.